ý ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2018 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 Form 10-K ¨ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission File No. 001-34186 VANDA PHARMACEUTICALS INC. (Exact name of registrant as specified in its charter) Delaware 03-0491827 (State or other jurisdiction of incorporation or organizat ...

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) Q4 2018 Earnings Conference Call February 13, 2019 4:30 PM ET Company Participants James Kelly - EVP and CFO Mihael Polymeropoulos - President and CEO Conference Call Participants Chris Howerton - Jefferies Joel Beatty - Citi Jason Butler - JMP Securities Pete Stavropoulos - Cantor Fitzgerald Esther Rajavelu - Oppenheimer Derek Archila - Stifel Operator Good day ladies and gentlemen and welcome to the Vanda Pharmaceutical’s fourth quarter 2018 earnings conference ca ...